Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/123199
Title: | A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS) |
Author: | Van Vollenhoven, Ronald F. Voskuyl, Alexandre E. Bertsias, George Aranow, Cynthia Aringer, Martin Arnaud, Laurent Askanase, Anca Balá ová, Petra Bonfa, Eloisa Bootsma, Hendrika Boumpas, Dimitrios Bruce, Ian N. Cervera i Segura, Ricard, 1960- Clarke, Ann E. Coney, Cindy Costedoat-Chalumeau, Nathalie Czirják, László Derksen, R. H. W. M. Doria, Andrea Dörner, Thomas Fischer-Betz, Rebecca Fritsch-Stork, Ruth Gordon, Caroline Graninger, Winfried Györi, Noémi Houssiau, Frédéric A. Isenberg, David Jacobsen, Søren Jayne, David Kuhn, Annegret Le Guern, Véronique Lerstrøm, Kirsten Levy, Roger A. Machado-Ribeiro, Francinne Mariette, Xavier Missaykeh, Jamil Morand, Eric Mosca, Marta Inanc, Murat Navarra, Sandra |
Keywords: | Lupus eritematós Malalties autoimmunitàries Farmacologia Estudi de casos Lupus erythematosus Autoimmune diseases Pharmacology Case studies |
Issue Date: | 24-Nov-2016 |
Publisher: | BMJ Publishing Group |
Abstract: | Objectives Treat-to-target recommendations have identified 'remission' as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE. Methods An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%. Results The task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions: 1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by . (reference to symptoms, signs, routine labs). 2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician's global assessment. 3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics. The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life. Conclusions The work of this international task force provides a framework for testing different definitions of remission against long-term outcomes. |
Note: | Reproducció del document publicat a: https://doi.org/10.1136/annrheumdis-2016-209519 |
It is part of: | Annals of the Rheumatic Diseases, 2016, vol. 76, num. 3, p. 554-561 |
URI: | http://hdl.handle.net/2445/123199 |
Related resource: | https://doi.org/10.1136/annrheumdis-2016-209519 |
ISSN: | 0003-4967 |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
678610.pdf | 533.34 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.